February 2026
Psychedelic-assisted therapy
What February 2026's 12 new studies found, synthesized from the papers below. All Psychedelic-assisted therapy research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psychedelic-assisted therapy, psychedelic therapy, assisted psychotherapy, drug-assisted therapy, then ranked by relevance.
Psychedelic-assisted therapies (PAP) show promising therapeutic potential for conditions like treatment-resistant depression, anxiety, anhedonia, and psycho-existential distress. Psilocybin and LSD-assisted psychotherapy significantly reduced depressive and anxiety symptoms in a real-world setting, and psilocybin significantly reduced anhedonia in TRD for up to six months. However, while ketamine-assisted psychotherapy was associated with symptom reductions, controlled studies found no significant difference from control conditions. A key caveat is the pervasive call for more rigorous, larger, placebo-controlled trials, especially for newer compounds, and to address methodological challenges like placebo effects and cultural considerations.
Confidence in the evidence
Moderate- Multiple reviews and primers suggest promising potential for various psychedelics (psilocybin, LSD, 5-MeO-DMT, mescaline) for conditions like TRD, anxiety, and psycho-existential distress.
- A secondary analysis of a randomized, waitlist-controlled trial (n=30) found significant and clinically relevant reductions in anhedonia with psilocybin-assisted psychotherapy, sustained up to 6 months.
- A retrospective analysis of real-world compassionate use data (n=115) showed significant decreases in depressive and anxiety symptoms with LSD or psilocybin.
- A systematic review on ketamine-assisted psychotherapy found symptom reductions but no significant differences from control conditions in controlled studies, indicating mixed efficacy evidence for KAP.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline 2026 | primer/review | Supports | Mescaline shows preliminary safety in healthy humans but remains understudied in clinical populations. | |
| Psychedelic therapy and cultural humility 2026 | commentary/review | Supports | Clinical trials of psilocybin and LSD assisted therapy demonstrate significant reductions in depression, anxiety, and demoralization among patients with life-limiting illness, but cultural factors require attention. | |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine 2026 | primer/review | Supports | Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions. | |
| Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review 2026 | narrative review | Supports | Psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation for psycho-existential distress in palliative settings. | |
| Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression 2026 | secondary analysis of RCT | 30 | Supports | Psilocybin-assisted psychotherapy significantly reduced anhedonia severity in individuals with treatment-resistant depression at 2 weeks, with clinically significant improvements at 3 and 6 months. |
| Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review. 2026 | systematic review | Mixed | Ketamine-assisted psychotherapy was associated with reductions in depressive symptoms, but controlled studies showed no significant differences between KAP and control conditions. | |
| Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland. 2026 | retrospective analysis | 115 | Supports | LSD or psilocybin-assisted psychotherapy in a compassionate-use cohort significantly decreased depressive and anxiety symptoms, with reduced self-blame, rumination, and catastrophizing. |
| Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis. 2026 | qualitative | 21 | Supports | Qualitative interviews with clinicians, researchers, and patients identified perceived therapeutic benefits of MDMA-assisted psychotherapy for PTSD. |
| Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance. 2026 | review | Unclear | Placebo effects, shaped by expectancy, therapeutic setting, and trial design, are important considerations for psychedelic-like compounds in depression treatment trials. | |
| Psychedelic-assisted psychotherapy: The Australian and general practice perspective 2026 | discussion/review | Supports | Meta-analyses of clinical trial results for psychedelic medication in psychotherapy have shown substantial effect sizes for treatment-resistant PTSD and depression. |
Mescaline shows preliminary safety in healthy humans but remains understudied in clinical populations.
primer/review
Clinical trials of psilocybin and LSD assisted therapy demonstrate significant reductions in depression, anxiety, and demoralization among patients with life-limiting illness, but cultural factors require attention.
commentary/review
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions.
primer/review
Psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation for psycho-existential distress in palliative settings.
narrative review
Psilocybin-assisted psychotherapy significantly reduced anhedonia severity in individuals with treatment-resistant depression at 2 weeks, with clinically significant improvements at 3 and 6 months.
secondary analysis of RCT Sample size: 30
Ketamine-assisted psychotherapy was associated with reductions in depressive symptoms, but controlled studies showed no significant differences between KAP and control conditions.
systematic review
LSD or psilocybin-assisted psychotherapy in a compassionate-use cohort significantly decreased depressive and anxiety symptoms, with reduced self-blame, rumination, and catastrophizing.
retrospective analysis Sample size: 115
Qualitative interviews with clinicians, researchers, and patients identified perceived therapeutic benefits of MDMA-assisted psychotherapy for PTSD.
qualitative Sample size: 21
Placebo effects, shaped by expectancy, therapeutic setting, and trial design, are important considerations for psychedelic-like compounds in depression treatment trials.
review
Meta-analyses of clinical trial results for psychedelic medication in psychotherapy have shown substantial effect sizes for treatment-resistant PTSD and depression.
discussion/review
Points of agreement
- Psychedelic-assisted therapy (PAP) shows promise for treatment-resistant depression, anxiety, and psycho-existential distress.
- Psilocybin and LSD are frequently mentioned as having therapeutic potential.
- Anhedonia in TRD is a specific symptom that PAP might address.
- The field acknowledges the need for more rigorous, controlled trials.
- Safety in controlled settings appears generally favorable, but long-term safety and safety in clinical populations with comorbidities need more study.
Conflicts
- Ketamine-assisted psychotherapy (KAP) was associated with symptom reductions in general, but controlled studies found no significant difference from control conditions, contrasting with generally positive signals for other psychedelics.
Gaps
- Lack of controlled clinical trials for mescaline and 5-MeO-DMT in patient populations.
- Unclear long-term safety and psychological risks for mescaline.
- Need for larger, placebo-controlled trials to confirm effects, especially for anhedonia.
- Methodological heterogeneity in KAP studies limits firm conclusions.
- Durability of effects for many interventions.
- Cultural portability and humility in treatment protocols.